119 related articles for article (PubMed ID: 32500781)
1. Hematologic parameters are not predictors of upgrading or treatment in a racially diverse prospective study of men with prostate cancer on active surveillance.
Shelton TM; Greenberg JW; Silberstein JL; Krane LS
Aging Male; 2020 Dec; 23(5):1400-1408. PubMed ID: 32500781
[TBL] [Abstract][Full Text] [Related]
2. Can systemic immune-inflammation index and hematologic parameters aid in decision-making for active surveillance or curative treatment in low-risk prostate cancer?
Baylan B; Ulusoy K; Ekenci B; Kartal IG
Asian J Surg; 2024 Mar; 47(3):1360-1365. PubMed ID: 38065745
[TBL] [Abstract][Full Text] [Related]
3. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
Ferro M; Musi G; Serino A; Cozzi G; Mistretta FA; Costa B; Bianchi R; Cordima G; Luzzago S; Di Trapani E; Tagliabue E; Vartolomei MD; Terracciano D; Cassatella MC; Salvatici M; Conti A; Sandri MT; Cioffi A; Turetti M; Catellani M; Bottero D; Matei DV; Mirone V; de Cobelli O
Urol Int; 2019; 102(1):43-50. PubMed ID: 30408799
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer.
Sun Z; Ju Y; Han F; Sun X; Wang F
J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28605139
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.
Kwon YS; Han CS; Yu JW; Kim S; Modi P; Davis R; Park JH; Lee P; Ha YS; Kim WJ; Kim IY
Clin Genitourin Cancer; 2016 Feb; 14(1):e1-8. PubMed ID: 26341038
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
8. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio.
Adhyatma KP; Prapiska FF; Siregar GP; Warli SM
Open Access Maced J Med Sci; 2019 May; 7(10):1628-1630. PubMed ID: 31210812
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios alone or combined with prostate-specific antigen for the diagnosis of prostate cancer and clinically significant prostate cancer.
Nepal SP; Nakasato T; Fukagai T; Ogawa Y; Nakagami Y; Shichijo T; Morita J; Maeda Y; Oshinomi K; Unoki T; Noguchi T; Inoue T; Kato R; Amano S; Mizunuma M; Kurokawa M; Tsunokawa Y; Yasuda S
Asian J Urol; 2023 Apr; 10(2):158-165. PubMed ID: 36942115
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.
Chen Z; Zhao G; Chen F; Xia J; Jiang L
BMC Cancer; 2019 Apr; 19(1):329. PubMed ID: 30961549
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
12. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
[TBL] [Abstract][Full Text] [Related]
13. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
14. Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors.
Goh BK; Chok AY; Allen JC; Quek R; Teo MC; Chow PK; Chung AY; Ong HS; Wong WK
Surgery; 2016 Apr; 159(4):1146-56. PubMed ID: 26688506
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
16. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
18. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer.
Hirahara T; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kita Y; Mori S; Sasaki K; Omoto I; Kurahara H; Maemura K; Okubo K; Uenosono Y; Ishigami S; Natsugoe S
BMC Cancer; 2019 Jul; 19(1):672. PubMed ID: 31286873
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]